Dyadic International Inc (DYAI)

$1.26

-0.01

(-0.79%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $1.22
    $1.26
    $1.26
    downward going graph

    3.17%

    Downside

    Day's Volatility :3.18%

    Upside

    0.01%

    downward going graph
  • $1.13
    $2.67
    $1.26
    downward going graph

    10.32%

    Downside

    52 Weeks Volatility :57.68%

    Upside

    52.81%

    downward going graph

Returns

PeriodDyadic International IncIndex (Russel 2000)
3 Months
-37.62%
0.0%
6 Months
-9.35%
0.0%
1 Year
-31.15%
0.0%
3 Years
-79.0%
-22.3%

Highlights

Market Capitalization
38.7M
Book Value
$0.11
Earnings Per Share (EPS)
-0.27
PEG Ratio
0.0
Wall Street Target Price
6.0
Profit Margin
0.0%
Operating Margin TTM
-528.5%
Return On Assets TTM
-46.28%
Return On Equity TTM
-127.38%
Revenue TTM
1.8M
Revenue Per Share TTM
0.06
Quarterly Revenue Growth YOY
-53.900000000000006%
Gross Profit TTM
807.1K
Diluted Eps TTM
-0.27
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.26
EPS Estimate Next Year
-0.21
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Dyadic International Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 376.19%

Current $1.26
Target $6.00

Company Financials

FY18Y/Y Change
Revenue
1.3M
↑ 70.81%
Net Income
-5.7M
↑ 166.49%
Net Profit Margin
-439.36%
↓ 157.75%
FY19Y/Y Change
Revenue
1.7M
↑ 29.77%
Net Income
-8.3M
↑ 45.96%
Net Profit Margin
-494.21%
↓ 54.85%
FY20Y/Y Change
Revenue
1.6M
↓ 4.71%
Net Income
-9.3M
↑ 12.24%
Net Profit Margin
-582.13%
↓ 87.92%
FY21Y/Y Change
Revenue
2.4M
↑ 50.06%
Net Income
-12.9M
↑ 38.57%
Net Profit Margin
-537.54%
↑ 44.59%
FY22Y/Y Change
Revenue
2.9M
↑ 21.9%
Net Income
-9.4M
↓ 27.48%
Net Profit Margin
-319.79%
↑ 217.75%
FY23Y/Y Change
Revenue
2.9M
↓ 1.07%
Net Income
-6.8M
↓ 27.48%
Net Profit Margin
-234.42%
↑ 85.37%
Q1 FY23Q/Q Change
Revenue
978.1K
↑ 31.51%
Net Income
137.6K
↓ 106.64%
Net Profit Margin
14.07%
↑ 292.69%
Q2 FY23Q/Q Change
Revenue
837.2K
↓ 14.41%
Net Income
-2.2M
↓ 1664.58%
Net Profit Margin
-257.17%
↓ 271.24%
Q3 FY23Q/Q Change
Revenue
397.1K
↓ 52.57%
Net Income
-1.6M
↓ 25.02%
Net Profit Margin
-406.55%
↓ 149.38%
Q4 FY23Q/Q Change
Revenue
686.5K
↑ 72.9%
Net Income
-2.1M
↑ 28.34%
Net Profit Margin
-301.78%
↑ 104.77%
Q1 FY24Q/Q Change
Revenue
334.6K
↓ 51.26%
Net Income
-2.0M
↓ 3.0%
Net Profit Margin
-600.57%
↓ 298.79%
Q2 FY24Q/Q Change
Revenue
385.9K
↑ 15.32%
Net Income
-2.0M
↑ 1.77%
Net Profit Margin
-529.99%
↑ 70.58%
FY18Y/Y Change
Total Assets
43.3M
↓ 14.67%
Total Liabilities
849.6K
↑ 10.5%
FY19Y/Y Change
Total Assets
37.5M
↓ 13.51%
Total Liabilities
1.6M
↑ 86.91%
FY20Y/Y Change
Total Assets
30.1M
↓ 19.71%
Total Liabilities
1.6M
↑ 2.38%
FY21Y/Y Change
Total Assets
21.3M
↓ 29.17%
Total Liabilities
2.9M
↑ 78.9%
FY22Y/Y Change
Total Assets
13.7M
↓ 35.62%
Total Liabilities
2.6M
↓ 9.75%
FY23Y/Y Change
Total Assets
8.2M
↓ 40.06%
Total Liabilities
2.3M
↓ 10.84%
Q1 FY23Q/Q Change
Total Assets
12.8M
↓ 6.57%
Total Liabilities
2.0M
↓ 23.53%
Q2 FY23Q/Q Change
Total Assets
11.1M
↓ 13.56%
Total Liabilities
2.1M
↑ 4.07%
Q3 FY23Q/Q Change
Total Assets
9.3M
↓ 16.42%
Total Liabilities
1.6M
↓ 23.27%
Q4 FY23Q/Q Change
Total Assets
8.2M
↓ 11.2%
Total Liabilities
2.3M
↑ 46.01%
Q1 FY24Q/Q Change
Total Assets
12.7M
↑ 54.29%
Total Liabilities
8.2M
↑ 248.85%
Q2 FY24Q/Q Change
Total Assets
10.6M
↓ 16.17%
Total Liabilities
7.5M
↓ 8.61%
FY18Y/Y Change
Operating Cash Flow
-4.4M
↑ 69.1%
Investing Cash Flow
3.3M
↓ 509.85%
Financing Cash Flow
-2.3M
↓ 63.04%
FY19Y/Y Change
Operating Cash Flow
-5.8M
↑ 31.21%
Investing Cash Flow
7.7M
↑ 131.57%
Financing Cash Flow
550.2K
↓ 123.93%
FY20Y/Y Change
Operating Cash Flow
-6.6M
↑ 13.69%
Investing Cash Flow
22.1M
↑ 187.02%
Financing Cash Flow
255.5K
↓ 53.57%
FY21Y/Y Change
Operating Cash Flow
-11.3M
↑ 71.53%
Investing Cash Flow
5.2M
↓ 76.4%
Financing Cash Flow
1.2M
↑ 381.49%
FY22Y/Y Change
Operating Cash Flow
-8.1M
↓ 28.32%
Investing Cash Flow
-2.4M
↓ 145.37%
Financing Cash Flow
543.6K
↓ 55.81%
Q1 FY23Q/Q Change
Operating Cash Flow
-2.2M
↑ 30.04%
Investing Cash Flow
2.8M
↑ 347.83%
Financing Cash Flow
0.0
↓ 100.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-1.7M
↓ 24.34%
Investing Cash Flow
1.1M
↓ 59.49%
Financing Cash Flow
0.0
-

Technicals Summary

Sell

Neutral

Buy

Dyadic International Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Dyadic International Inc
Dyadic International Inc
-6.67%
-9.35%
-31.15%
-79.0%
-76.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.97%
16.25%
37.11%
69.18%
305.56%
Novo Nordisk A/s
Novo Nordisk A/s
9.99%
-3.52%
34.24%
158.74%
417.73%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-5.15%
64.67%
22.72%
31.08%
198.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.45%
14.0%
36.06%
143.5%
167.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Dyadic International Inc
Dyadic International Inc
NA
NA
0.0
-0.26
-1.27
-0.46
NA
0.11
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.93
29.93
1.54
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
44.01
44.01
1.98
3.44
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Dyadic International Inc
Dyadic International Inc
Buy
$38.7M
-76.84%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$124.7B
305.56%
29.93
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$585.3B
417.73%
44.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.3B
198.44%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.9B
167.72%
32.84
-4.74%

Insights on Dyadic International Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 334.61K → 385.89K (in $), with an average increase of 13.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -2.00M → -2.04M (in $), with an average decrease of 1.8% per quarter

  • Vs REGN

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 68.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 148.2%

Institutional Holdings

  • Bandera Partners LLC

    5.32%

  • Chapin Davis Inc

    2.87%

  • Vanguard Group Inc

    2.73%

  • Northeast Financial Consultants, Inc

    0.85%

  • BlackRock Inc

    0.85%

  • Geode Capital Management, LLC

    0.76%

Company Information

dyadic international, inc. (otcqx: dyai) - we are a global biotechnology company focused on further improving and leveraging the patented and proprietary c1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system - but most importantly to save lives.

Organization
Dyadic International Inc
Employees
7
CEO
Mr. Mark A. Emalfarb
Industry
Biotechnology

Discover More

FAQs